Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial.

Journal: PloS one

Volume: 9

Issue: 8

Year of Publication: 2015

Affiliated Institutions:  Massachusetts General Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; The Fenway Institute, Fenway Health, Boston, MA, United States of America. The Fenway Institute, Fenway Health, Boston, MA, United States of America; Harvard School of Public Health, Boston, MA, United States of America. Harvard School of Public Health, Boston, MA, United States of America. Massachusetts General Hospital, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America; The Fenway Institute, Fenway Health, Boston, MA, United States of America; Harvard School of Public Health, Boston, MA, United States of America. Frontier Science and Technology Research Foundation, Amherst, NY, United States of America. Asociacion Civil Impacta Salud y Educacion, Lima, Peru. Alpert Medical School/The Miriam Hospital, Providence, RI, United States of America. College of Medicine - Johns Hopkins Research Project, Blantyre, Malawi. University of North Carolina Project, Lilongwe, Malawi. University of Zimbabwe-University of California San Francisco Collaborative Research Program, Harare, Zimbabwe. National AIDS Research Institute, Pune, India. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America. NIH/NIAD/DAIDS Pharmaceutical Affairs, Bethesda, MD, United States of America. Massachusetts General Hospital, Boston, MA, United States of America. Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, S. Africa. YRGCARE Medical Centre, Chennai, India. University of Zimbabwe, Harare, Zimbabwe, Africa. University of Colorado Denver, Aurora, CO, United States of America.

Abstract summary 

PEARLS, a large scale trial of antiretroviral therapy (ART) for HIV (n = 1,571, 9 countries, 4 continents), found that a once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC), but not a once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF), had inferior efficacy compared to a standard of care twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV). The present study examined non-adherence in PEARLS.Outcomes: non-adherence assessed by pill count and by self-report, and time to treatment failure. Longitudinal predictors: regimen, quality of life (general health perceptions  =  QOL-health, mental health  =  QOL-mental health), social support, substance use, binge drinking, and sexual behaviors. "Life-Steps" adherence counseling was provided.In both pill-count and self-report multivariable models, both once-a-day regimens had lower levels of non-adherence than the twice-a-day standard of care regimen; although these associations attenuated with time in the self-report model. In both multivariable models, hard-drug use was associated with non-adherence, living in Africa and better QOL-health were associated with less non-adherence. According to pill-count, unprotected sex was associated with non-adherence. According to self-report, soft-drug use was associated with non-adherence and living in Asia was associated with less non-adherence. Both pill-count (HR = 1.55, 95% CI: 1.15, 2.09, p<.01) and self-report (HR = 1.13, 95% CI: 1.08, 1.13, p<.01) non-adherence were significant predictors of treatment failure over 72 weeks. In multivariable models (including pill-count or self-report nonadherence), worse QOL-health, age group (younger), and region were also significant predictors of treatment failure.In the context of a large, multi-national, multi-continent, clinical trial there were variations in adherence over time, with more simplified regimens generally being associated with better adherence. Additionally, variables such as QOL-health, regimen, drug-use, and region play a role. Self-report and pill-count adherence, as well as additional psychosocial variables, such QOL-health, age, and region, were, in turn, associated with treatment failure.

Authors & Co-authors:  Safren Steven A SA Biello Katie B KB Smeaton Laura L Mimiaga Matthew J MJ Walawander Ann A Lama Javier R JR Rana Aadia A Nyirenda Mulinda M Kayoyo Virginia M VM Samaneka Wadzanai W Joglekar Anjali A Celentano David D Martinez Ana A Remmert Jocelyn E JE Nair Aspara A Lalloo Umesh G UG Kumarasamy Nagalingeswaran N Hakim James J Campbell Thomas B TB

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Bämighausen T (2007) Access to antiretroviral treatment in the developing world: a framework, review and health systems research agenda. Therapy 4: 753–766.
Authors :  20
Identifiers
Doi : e104178
SSN : 1932-6203
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
Study Design
Longitudinal Study
Study Approach
Country of Study
Publication Country
United States